ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Listening to the patient for better outcomes
Implementing patient-centricity within a clinical trials starts with listening to the patient voice.
What clinical holds and pauses mean for COVID-19 countermeasure timelines
ICON’s Nuala Murphy and David Morse discuss trial pauses and clinical halts after three high-profile COVID-19 trials are temporarily halted.
This PharmaTimes article considers how drug sponsors can navigate a path to reimbursement success and market access for drugs that were in development prior to the pandemic.
Navigating cell therapy manufacturing amid pandemic woes
An article featuring expert commentary from ICON's Tamie Joeckel on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
This published study conducted by ICON's Health Economics team and Bristol-Myers Squibb evaluates a cost-effective new treatment for melanoma patients in Japan.
Planning a managed access programme: Advice for clinical teams
ICON's Veronica Gutierrez Martinez considers how Sponsors need to plan carefully before undertaking a MAP so that they have the resources, processes, and tools in place to support the inevitable demand.
The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies
ICON's Richard Pitman joins global public health experts to address the importance of flu vaccination programs amid the COVID-19 pandemic.
How to measure your patient-centric impact
A patient insight article authored by ICON's Maggie Adamski on the benefit of patient centric clinical trial design.
Developing enhanced digital content to increase physician engagement
With in-person scientific congresses an impossibility for the foreseeable future, researchers and publishers have to adapt how they foster scientific exchange. Experts from ICON's Medical Communications team discuss how they are using enhanced media fit for the digital age.
High-sensitivity flow cytometric assays: Considerations for design control and analytical validation for identification of rare events
This scientific paper examines practices for the development, optimisation, and analytical validation of flow cytometric assays designed to assess rare events.